References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailrelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Ferrari, S.; ADAMI, S.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 49-50

Detailed reference viewed: 41 (2 ULg)
Full Text
Peer Reviewed
See detailA randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P.; Pannacciulli, N.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(SUPPLEMENT1), 42

Detailed reference viewed: 45 (2 ULg)
Full Text
Peer Reviewed
See detailBalancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Cooper, C.; Bardin, T.; Brandi, M.L. et al

in Aging Clinical and Experimental Research (2016), 28(1), 1-16

Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid ... [more ▼]

Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid arthritis (RA), and whether its side effects can be adequately managed. Recent basic and clinical research on the molecular, cellular and clinical effects of GCs have considerably advanced our knowledge in this field. An overview of the subject seems appropriate. Methods: This review is the result of a multidisciplinary expert working group, organised by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. The recent literature was surveyed and the salient evidence synthetized. Results: The pathophysiological basis of RA (and other inflammatory rheumatic diseases) now strongly implicates the adaptive immune system in addition to innate mechanisms. The molecular effect of GCs and differential GC sensitivity is better understood, although exploiting this knowledge is still in its infancy. The newer treatment strategies of early and aggressive control of RA have greatly improved clinical outcomes, but improvements are still possible. Newer targeted anti-inflammatory drugs have made an important impact, yet they too are associated with numerous side effects. Discussion: Short durations of moderate doses of GCs are generally well tolerated and have a positive benefit/risk ratio. Patients should be assessed for fracture risk and bone preserving agents and be prescribed calcium and vitamin D supplementation. Conclusions: Within a strategy of a disease modifying approach to inflammatory disease, combination therapy including a GC is effective approach. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier ULg; Cooper, Cyrus et al

in Drugs & Aging (2016), 33(2), 75-85

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been ... [more ▼]

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated [less ▲]

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis and sarcopenia: two diseases or one?
Reginster, Jean-Yves ULg; Beaudart, Charlotte ULg; Buckinx, Fanny ULg et al

in Current Opinion in Clinical Nutrition & Metabolic Care (2016), 19(1), 31-6

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies ... [more ▼]

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies support the concept of a bone–muscle unit, where constant cross-talking between the two tissues takes place, involving molecules released by the skeletal muscle secretome, which affects bone, and osteokines secreted by the osteoblasts and osteocytes, which, in turn, impact muscle cells. Summary New chemical entities aiming at concomitantly treating osteoporosis and sarcopenia could be developed by targeting pathways that centrally regulate bone and muscle or emerging pathways that facilitate the communication between the two tissues. [less ▲]

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailDeterminants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Cavalier, Etienne ULg et al

in Osteoporosis International (2016), 27

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 ... [more ▼]

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. Introduction The aim of this study is to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Methods General practitioners (GPs) having at least one patient in a nursing home in Liège, Belgium, were asked to complete the survey. Results A total of 119 GPs participated in the survey. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. The main reasons for prescribing vitamin D cited by GPs who do so systematically are as follows: because they believe nursing home residents are mostly deficient in vitamin D status (92.1 %), because they believe that vitamin D supplementation prevents osteoporotic fractures (77.8 %), and because vitamin D supplementation is recommended by various scientific societies (38.1 %). GPs who only prescribe vitamin D supplementation in some patients mainly do so following a diagnosis of osteoporosis (82.4 %), on the basis the 25(OH)D level (78.4 %), in the case of history of fracture (54.9 %) or after a recent fracture (43.4 %). Surprisingly, 16 physicians (31.4 %) only prescribe vitamin D when they think of it. Interestingly, while 40.7% of GPs always prescribe the same dose of vitamin D, the remaining 59.3 % prescribe a dose that will mainly depend on the results of the 25(OH)D level (94.0 %), the patient’s bone health (49.3 %), or history of fracture (43.3 %). Conclusions More than half of GPs systematically prescribe vitamin D to their patients living in nursing homes. The other GPs usually prescribe vitamin D following the result of the vitamin D status or after a diagnosis of osteoporosis. [less ▲]

Detailed reference viewed: 50 (27 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures
Ethgen, Olivier ULg; Hiligsmann, Mickaël; Burlet, Nansa et al

in Osteoporosis International (2016), 27

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of ... [more ▼]

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of osteoporotic fractures. Introduction: The objective of this study is to assess the costeffectiveness of the vitamin D-fortified yogurt given to women with and without an increased risk of osteoporotic fracture. Methods: Avalidated cost-effectiveness microsimulation Markov model of osteoporosis management was used. Three personalized supplementation scenarios to reflect the Ca/Vit D needs taking into account the well-known variations in dietary habits and a possible pharmacological supplementation in Ca/ Vit D, given above or in combination with anti-osteoporosis medications: one yogurt per day, i.e., 400 mg of Ca+200 IU of Vit D (scenario 1 U), two yogurts per day, i.e., 800 mg of Ca+ 400 IU of Vit D (scenario 2 U), or three yogurts per day, i.e., 1, 200 mg of Ca+600 IU of Vit D (scenario 3 U). Results: One yogurt is cost-effective in the general population above the age of 70 years and in all age groups in women with low bone mineral density (BMD) or prevalent vertebral fracture (PVF). The daily intake of two yogurts is cost-effective above 80 years in the general population and above 70 years in the two groups of women at increased risk of fractures. However, an intake of three yogurts per day is only cost-effective above 80 years old in the general population, as well as in women with low BMD or PVF. Conclusions: Our study is the first economic analysis supporting the cost-effectiveness of dairy products, fortified with vitamin D, in the armamentarium against osteoporotic fractures. [less ▲]

Detailed reference viewed: 18 (7 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient content of food served and consumed by nursing home residents
Buckinx, Fanny ULg; ALLEPAERTS, Sophie ULg; PAQUOT, Nicolas ULg et al

in the journal of nutrition, health & aging (2016), in press

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food ... [more ▼]

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food intake and dietary allowances. Design: This is a cross sectional study. Setting: This study was performed in nursing homes. Participants: Residents of these 2 nursing homes were eligible for the study if they agreed to participate and if they meet the selection criteria (to be older than 65 years and have a regular texture diet). Measurement: Nutrient content of the served food and real food consumption was calculated for all meals during a 5-day period by precise weighting method. Difference between consumed and served dietary content was evaluated by the Chi² test. Results: Seventy-four Belgian nursing home residents (75% of women, 85.8 ± 7.04 years on average) were included in this study. These subjects had a mean body mass index of 24.9 ± 4.83 kg/m². The mean energy content of the served food was 1783.3 ± 125.7 kcal per day. However, residents did not eat the whole of the meals and the actual energy content of the consumed food was significantly less (1552.4 ± 342.1 kcal per day; p<.001). The average protein content of the food served was equal to 0.96 ± 0.20 g/kg/day and the average consumption of protein by the residents was 0.88 ± 0.25 g/kg/day. The difference between protein served and consumed was also significant (p=.04). Moreover, people considered as well nourished, eating significantly more energy than the others (p=.04). Conclusion: Meals served in nursing homes are not entirely consumed by their residents. As expected, the energy consumed are lower in subjects considered as malnourished or at risk of malnutrition. [less ▲]

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in elderly women from the SarcoPhAge cohort: preliminary results
Locquet, Médéa ULg; Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg et al

in Journal of Frailty & Aging (2016)

Background: Recent studies suggest that bone and muscle wasting are closely interconnected. Objective: The aim was of this study is to assess the prevalence of osteoporosis in a population of women ... [more ▼]

Background: Recent studies suggest that bone and muscle wasting are closely interconnected. Objective: The aim was of this study is to assess the prevalence of osteoporosis in a population of women diagnosed with sarcopenia. Participants, setting and design: We analyzed cross-sectional data of women, aged 65 years and above, for whom bone mineral density was available at the time of inclusion in the SarcoPhAge (Sarcopenia and Physical impairment with advancing Age) cohort, an ongoing prospective study with the aim to assess consequences of sarcopenia. Measurements: Muscle strength was evaluated with a hydraulic hand-dynamometer, appendicular lean mass and bone mineral density by Dual-Energy X-Ray Absorptiometry and physical performance by the Short Physical Performance Battery test (SPPB). Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People definition, i.e. a low muscle mass plus either low muscle strength or low physical performance. A bone mineral density T-score equal to or below -2.5SD at the lumbar spine, at the total hip or at the femoral neck was used to define osteoporosis (World Health Organization definition). Results: A total of 126 women aged 74.38±6.32 years were included. Among them, 26 were assessed with sarcopenia (20.6%) and 34 (27.0%) with osteoporosis. There were more osteoporotic women among sarcopenic subjects (46.1%) than among non-sarcopenic subjects (22.0%) (p-value=0.011). A significant lower appendicular lean mass index was observed in osteoporotic women (p-value=0.025). We also observed, in osteoporotic subjects, a lower muscle strength (p-value=0.023). Numerical values of bone mineral density were lower in the sarcopenic population but the differences did not reach the level of statistical significance. Conclusion: Our study demonstrated that muscle mass and strength are lower in patients with osteoporosis. Prospective changes in bone and muscle mass will be investigated during the follow-up of our cohort. [less ▲]

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailOstéoporose et sarcopénie: un même combat ?
Locquet, Médéa ULg; Bruyère, Olivier ULg; Beaudart, Charlotte ULg et al

in Ortho-Rhumato (2016), 14(4), 34-36

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la ... [more ▼]

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la morbidité et de la mortalité. Elles représentent toutes deux un problème de santé publique grandissant, impliquant également des coûts de santé importants. Certaines études récentes confirment l’existence d’une unité fonctionnelle «os-muscle», concernant notamment ses aspects biologiques, hormonaux, développementaux ou encore génétiques. Actuellement, quelques études scientifiques démontrent également l’existence de voies communes dans la pathogenèse de la perte de masse musculaire et de masse osseuse. Certains auteurs suggèrent que les dysfonctionnements de cette unité fonctionnelle «os-muscle» pourraient éventuellement conduire à une pathologie spécifique, affectant les deux structures et pour lequel le terme «ostéosarcopénie» a été proposé. Cependant, jusqu’à présent, l’étroite relation entre muscles et os reste très peu explorée par les études cliniques en ce qui concerne ses aspects pathologiques et, plus particulièrement, le lien existant entre sarcopénie et ostéoporose, ses déterminants et ses conséquences. Ce manque de connaissances implique donc des retentissements considérables pour les politiques de santé publique, principalement concernant les stratégies préventives et thérapeutiques susceptibles d’être proposées aux personnes âgées. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailPotential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
Penton, H; Hiligsmann, M.; Harrison, M. et al

in Osteoporosis International (2016), 27

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence ... [more ▼]

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence, and only marginally increased time physicians needed with their patients, then the decision-aid would be cost-effective. Introduction Oral bisphosphonates have been shown to reduce the risk of osteoporotic fracture. Adherence is crucial but suboptimal. A recent study suggests that a patient decision aid, which facilitates shared decision-making, could be effective in increasing adherence to bisphosphonates. But decision aids come at a cost in terms of additional time spent with physicians. This study considers the emerging evidence on the role of patient decision aids in improving adherence to bisphosphonates and their potential costs to inform future decision-making and research priorities. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailA Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.
Detilleux, Johann ULg; REGINSTER, Jean-Yves ULg; Chines, A. et al

in Statistical Methods in Medical Research (2016), 25(1), 400-412

Background/Aims Bone mass density values have been related with risk of vertebral fractures in post-menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture ... [more ▼]

Background/Aims Bone mass density values have been related with risk of vertebral fractures in post-menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture, which decreases its usefulness as a surrogate in clinical trials. We propose a modeling framework with three interconnected parts to improve the evaluation of bone mass density accuracy in forecasting fractures after treatment. Methods The modeling framework includes: (1) a piecewise regression to describe non-linear temporal BMD changes more accurately than crude percent changes, (2) a structural equation model to analyze interdependencies among vertebral fractures and their potential risk factors in preference to regression techniques that consider only directional associations, and (3) a counterfactual causal interpretation of the direct and indirect relationships between treatment and occurrence of vertebral fractures. We apply the methods to BMD repeated measurements from a study of the effect of bazedoxifene acetate on incident vertebral fractures in three different geographical regions. Results We made four observations: (1) bone mass density changes varied largely across participants, (2) baseline age and body mass index influenced baseline bone mass density that, in turn, had an effect on prevalent fractures, (3) direct and/or indirect effects of bazedoxifene acetate on incident fractures were different across regions, and (4) estimates of indirect effects were sensible to the presence of post-treatment unmeasured confounders. In one region, around 40% of the bazedoxifene acetate effect on the occurrence of fracture is explained by its effect on bone mass density. Under the counterfactual approach, these 40% represent the average difference in the occurrence of fracture observed for untreated individuals when their bone mass density values are set at the value under bazedoxifene acetate versus under placebo. Conclusions Computational methods are available to evaluate and interpret the surrogacytic capability of a biomarker of a primary outcome. © SAGE Publications 2012. [less ▲]

Detailed reference viewed: 48 (21 ULg)
Full Text
Peer Reviewed
See detailSarcopenia as a public health problem
Bruyère, Olivier ULg; Beaudart, Charlotte ULg; Locquet, Médéa ULg et al

in European Geriatric Medicine (2016)

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an ... [more ▼]

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an effective treatment. In this paper, we review the main current literature on sarcopenia in order to assess whether this geriatric syndrome could be considered as a major public health problem. Our review highlights that based on its prevalence, its clinical consequences, the limitations of the current available treatments as well as on the fact that many frail patients are affected by this geriatric syndrome, sarcopenia should be considered as a health priority by all interested parties in order to reduce its burden. [less ▲]

Detailed reference viewed: 34 (7 ULg)
Full Text
Peer Reviewed
See detailHigh Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study
Edwards, M.H.; Parsons, C.; Bruyère, Olivier ULg et al

in Journal of Rheumatology (2016), 43(3), 657-65

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change ... [more ▼]

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change in joint space width (JSW). Methods. A total of 559 men and women over the age of 50 years with clinical knee OA [Kellgren-Lawrence (KL) grade 2-3] were recruited to the placebo arm of the SEKOIA study (98 centers; 18 countries). Minimal tibiofemoral joint space and KL grade on plain radiograph of the knee were assessed at baseline and at yearly followup up to 3 years. In a subset, serial knee MRI examinations were performed. Individuals with a bone marrow lesion (BML) ≥ grade 2 at the tibiofemoral joint at baseline were classified as BML-positive. Relationships between change in JSW and risk factors were assessed using linear regression. Results. The mean age of study participants was 62.8 (SD 7.5) years and 73% were female; 38.6% had BML. Mean baseline JSW was 3.65 mm. This reduced by 0.18 (0.30) mm/year in men and 0.13 (0.23) mm/year in women. Those with BML had a significantly higher rate of annualized change in JSW; this relationship remained robust after adjustment for age, sex, and baseline KL grade [β = –0.10 (95% CI –0.18, –0.02) mm/yr]. Age, sex, baseline KL grade, and other MRI findings did not influence the rate of change in JSW. Conclusion. The rate of change in JSW was similar in men and women. BML on knee MRI predicted the rate of radiographic change in JSW. This relationship was independent of age, sex, and baseline KL grade. (First Release January 15 2016; J Rheumatol 2016;43:657–65; doi:10.3899/jrheum.150053) [less ▲]

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
SMOLEN, J.S.; COLLAUD BASSET, S.; BOERS, M. et al

in Annals of Rheumatic Diseases (2016), 75

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft ‘Guideline on clinical investigation of medicinal products for the treatment of RA’ released by the European Medicines Agency (EMA). Special emphasis was placed by the group on the development of new drugs for the treatment of early RA. In the absence of a clear definition of early RA, it was suggested that clinical investigations in this condition were conducted in disease-modifying antirheumatic drugs naïve patients with no more than 1 year disease duration. The expert group recommended using an appropriate improvement in disease activity (American College of Rheumatology (ACR) or Simplified/Clinical Disease Activity Index (SDAI/CDAI) response criteria) or low disease activity (by any score) as primary endpoints, with ACR/European League Against Rheumatism remission as a secondary endpoint. Finally, as compelling evidence showed that the Disease Acrivity Score using 28-joint counts (DAS28) might not provide a reliable definition of remission, or sometimes even low disease activity, the group suggested replacing DAS28 as a measurement instrument to evaluate disease activity in RA clinical trials. Proposed alternatives included SDAI, CDAI and Boolean criteria. [less ▲]

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, Jean-Yves ULg; Cooper, Cyrus; Rizzoli, René et al

in Aging Clinical and Experimental Research (2016), 28(1), 47-58

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a ... [more ▼]

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. Methods: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. Results A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a pleais made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. Conclusions : The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk. [less ▲]

Detailed reference viewed: 32 (12 ULg)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study
Locquet, Médéa ULg; Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 84

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailBrain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations
CAVALIER, Etienne ULg; Carlisi, A.S.; WATAR, Florence ULg et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 116

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailPhysical and muscle performances among elderly nursing home residents. Results fo the senior cohort
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; CROISIER, Jean-Louis ULg et al

in Journal of Frailty & Aging (2016), 5(Supplement 1), 69

Detailed reference viewed: 18 (2 ULg)